Pentoxyphilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsis

Medical Science Monitor

Volumn 10, Issue 7, 2004, Pages

  Modzelewski, Bogdan ^a,b   Janiak, Adam ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Lipid peroxydation; Pentoxyphilline; Peritonitis; Sepsis

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1BETA; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR P55; TUMOR NECROSIS FACTOR RECEPTOR P75; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; LIPID PEROXIDATION; MALE; NONHUMAN; PERITONITIS; PROTEIN BLOOD LEVEL; RAT; RAT STRAIN; SEPSIS; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTIGENS, CD; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1; ISOENZYMES; MALE; PENTOXIFYLLINE; PERITONITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEPSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3342933147     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lo CJ, Fu M, Lo FR, Cryer HG: Cyclooxygenase (COX-2) gene activation is regulated by cyclic adenosine monophosphate. Shock, 2000; 13(1): 41-45
2. Koo DJ, Yoo P, Cioffi WG et al: Mechanism of the beneficial effects of pentoxyphilline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res, 2000; 91(1): 70-76
3. Wu CC, Liao MH, Chen SJ, Yen MH. Pentoxyphilline improves circulatory failure and survival in murine models of endotoxemia. Eur J Pharmacol, 1999; 373: 41-49
4. Sharma VK, Dellinger RP: Recent developments in the treatment of sepsis. Expert Opin Investig Drugs, 2003; 12(2): 139-52
5. Zhang FX, Kirschning CJ, Mancinelli R: Bacterial lipopolysaccharide activates nuclear factor - kappaB through in terleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem, 1999; 274: 7611-14
6. Jimenez JL, Punzon C, Navarro J et al: Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-α and nuclear factor of activated T cells activation. J Pharmacol Exp Ther, 2001; 299(2): 753-59
7. Kocdor MA, Kocdor H, Gulay Z, Gokce O: The effects of pentoxyphilline on bacterial translocation after intestinal obstruction. Shock, 2002; 18(2): 148-51
8. Nelson JL, Alexander JW, Mao JX et al: Effect of pentoxyphilline on survival and intestinal cytokine messenger RNA transcription in a rat model of ongoing peritoneal sepsis. Crit Care Med, 1999; 27:113-19
9. Colson A, Willems B, Thissen JP: Inhibition of TNF-alpha production by pentoxyphilline does not prevent endotoxin-induced decrease in serum IGF-I. J Endocrinol, 2003; 178(1): 101-19
10. van der Bruggen T, Nijenhuis S, van Raaij E: Lipopolisaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1- MEK2/ERK1-ERK2 pathway. Infect Immun, 1999; 67: 3824-29
11. Modzelewski B: Release of tumor necrosis factor alpha and its soluble receptor p55 in clinical septic syndrome. Arch Immunol Ther Exp, 1997; 45: 213-19
12. Ferreira L, Perez-Gonzales N, Llanillo M et al: Acute pancreatitis decreases phospholipid peroxidation levels in rat pancreas. Lipids, 2002; 37(2): 167-71
13. Otero-Anton E, Gonzalez-Quintela A, Lopez-Soto A et al: Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res, 2001; 33(2): 77-79
14. Butty VL, Roux-Lombard P, Garbino J et al: Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis. Eur Cytokine Netw, 2003; 14(1): 15-19
15. Lauterbach R, Pawlik D, Kowalczyk D et al: Effect of the immunomodulating agent, pentoxyphilline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double blind trial. Crit Care Med, 1999; 27: 807-14
16. Modzelewski B: Soluble TNF p55 and p75 receptors in the development of sepsis syndrome. Pol Merkuriusz Lek, 2003; 14(79): 69-72
17. Bohuslav J, Kravchenko VV, Parry GC: Regulation of an essential innate immune response by the p50 subunit of NF-ȩâ. J Clin Invest, 1998; 102: 1645-52
18. Krysztopik RJ, Matheson PJ, Spain DA et al: Lazaroid and pentoxyphilline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res, 2000; 93(1): 75-81
19. Pfeffer K: Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev, 2003; 14(3-4): 186-91
20. Parker SJ, Brown D, Kenward CE, Watkins PE: Pentoxyphilline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis. Resuscitation, 2000; 44(1): 61-69
21. Ajuebor MN, Gibbs L, Flower LJ: Investigation of the functional role played by the chemokine monocyte chemoattractant protein-I in interleukin-I induced murine peritonitis. Br J Pharmacol, 1998; 125: 319-26
22. Zanotti S, Kumar A, Kumar A: Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs, 2002; 11(8): 1061-75